<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Cereb Blood Flow Metab</journal-id><journal-id journal-id-type="iso-abbrev">J Cereb Blood Flow Metab</journal-id><journal-id journal-id-type="pmc-domain-id">1259</journal-id><journal-id journal-id-type="pmc-domain">jcbfm</journal-id><journal-id journal-id-type="publisher-id">JCB</journal-id><journal-title-group><journal-title>Journal of Cerebral Blood Flow &amp; Metabolism</journal-title></journal-title-group><issn pub-type="ppub">0271-678X</issn><issn pub-type="epub">1559-7016</issn><publisher><publisher-name>SAGE Publications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11994644</article-id><article-id pub-id-type="pmcid-ver">PMC11994644.1</article-id><article-id pub-id-type="pmcaid">11994644</article-id><article-id pub-id-type="pmcaiid">11994644</article-id><article-id pub-id-type="pmid">40219925</article-id><article-id pub-id-type="doi">10.1177/0271678X251332487</article-id><article-id pub-id-type="publisher-id">10.1177_0271678X251332487</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>In vivo quantification of [<sup>11</sup>C]BIO-1819578 in non-human primates, a novel radioligand for O-GlcNAcase</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7728-6401</contrib-id><name name-style="western"><surname>Bolin</surname><given-names initials="M">Martin</given-names></name><xref rid="aff1-0271678X251332487" ref-type="aff">1</xref><xref rid="corresp1-0271678X251332487" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nag</surname><given-names initials="S">Sangram</given-names></name><xref rid="aff1-0271678X251332487" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Arakawa</surname><given-names initials="R">Ryosuke</given-names></name><xref rid="aff1-0271678X251332487" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8281-4435</contrib-id><name name-style="western"><surname>Varrone</surname><given-names initials="A">Andrea</given-names></name><xref rid="aff1-0271678X251332487" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Farde</surname><given-names initials="L">Lars</given-names></name><xref rid="aff1-0271678X251332487" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Martarello</surname><given-names initials="L">Laurent</given-names></name><xref rid="aff2-0271678X251332487" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kaliszczak</surname><given-names initials="MA">Maciej A</given-names></name><xref rid="aff3-0271678X251332487" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Halldin</surname><given-names initials="C">Christer</given-names></name><xref rid="aff1-0271678X251332487" ref-type="aff">1</xref><xref rid="aff4-0271678X251332487" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mor&#233;n</surname><given-names initials="AF">Anton Forsberg</given-names></name><xref rid="aff1-0271678X251332487" ref-type="aff">1</xref></contrib><aff id="aff1-0271678X251332487">
<label>1</label>Centre for Psychiatry Research, Department of Clinical Neuroscience, <institution-wrap><institution-id institution-id-type="Ringgold">27106</institution-id><institution>Karolinska Institutet</institution></institution-wrap>, &amp; Stockholm Health Care Services, Region Stockholm, Sweden</aff><aff id="aff2-0271678X251332487">
<label>2</label>Sentonix Inc., 1167 Massachusetts Ave., Arlington, MA, USA</aff><aff id="aff3-0271678X251332487">
<label>3</label>BIOGEN MA Inc., Cambridge, MA, USA</aff><aff id="aff4-0271678X251332487">
<label>4</label>Department of Biophysics and Radiation Biology, and HUN-REN TKI, <institution-wrap><institution-id institution-id-type="Ringgold">37637</institution-id><institution content-type="university">Semmelweis University</institution></institution-wrap>, Budapest, Hungary</aff></contrib-group><author-notes><corresp id="corresp1-0271678X251332487">Martin Bolin, Solnav&#228;gen 30, 17164 Solna, Sweden. Email: <email>martin.bolin@ki.se</email></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>4</month><year>2025</year></pub-date><issue-id pub-id-type="pmc-issue-id">475079</issue-id><elocation-id>0271678X251332487</elocation-id><history><date date-type="received"><day>12</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>19</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>17</day><month>3</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>04</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>14</day><month>04</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-04-15 00:25:13.907"><day>15</day><month>04</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder content-type="society">International Society for Cerebral Blood Flow and Metabolism</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution 4.0 License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_0271678X251332487.pdf"/><abstract><p>Neurofibrillary tangles (NFTs), composed of aggregated tau protein, in the brain is a neuropathological hallmark and feature of Alzheimer&#8217;s disease (AD) and other tauopathies. One promising approach to prevent tau aggregates is to inhibit O-GlcNAcase (OGA), an enzyme that regulates tau O-GlcNAcylation. [<sup>11</sup>C]BIO-1819578 has emerged as a promising candidate to determine target occupancy of such OGA inhibitor drugs. The aim of this study was to further evaluate the pharmacokinetic properties of [<sup>11</sup>C]BIO-1819578 in non-human primates (NHPs) and to estimate its effective dose. Kinetic compartment analyses of [<sup>11</sup>C]BIO-1819578 binding to OGA in the brain were performed on positron emission tomography (PET) measurements conducted in three cynomolgus NHPs. Whole-body PET measurements were carried out in two NHPs to estimate the effective radiation dose. Both the 1-tissue-compartment (1TCM) and 2-tissue-compartment model (2TCM) could describe the regional time activity curves of [<sup>11</sup>C]BIO-1819578. The 2TCM was the statistically preferred model. The effective radiation dose was estimated to be 0.0033&#8201;mSv/MBq. The results showed that [<sup>11</sup>C]BIO-1819578 has suitable characteristics for reliable quantification of OGA using full kinetic modelling. The effective dose was on par with other <sup>11</sup>C radioligands and is unlikely to pose an issue for human use.</p></abstract><kwd-group><kwd>Alzheimer</kwd><kwd>kinetic modelling</kwd><kwd>O-GlcNAcase</kwd><kwd>OGA</kwd><kwd>PET</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>edited-state</meta-name><meta-value>corrected-proof</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts2</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-0271678X251332487"><title>Introduction</title><p>The presence of neurofibrillary tangles (NFTs) in the brain is one of the neuropathological hallmarks of Alzheimer&#8217;s disease (AD). These intraneuronal tangles contain fibrillary structures that are formed by the aggregation of hyperphosphorylated microtubular-associated tau protein.<sup>
<xref rid="bibr1-0271678X251332487" ref-type="bibr">1</xref>
</sup> An increase in intracellular tau aggregates is highly linked to more severe disease states of AD and other tauopathies.<sup>
<xref rid="bibr2-0271678X251332487" ref-type="bibr">2</xref>
</sup> These observations have encouraged efforts to develop treatment approaches that can slow down or prevent the formation of pathological tau.<sup><xref rid="bibr3-0271678X251332487" ref-type="bibr">3</xref>,<xref rid="bibr4-0271678X251332487" ref-type="bibr">4</xref></sup> Diverse therapeutic strategies have been proposed to reduce tau expression or inhibit the formation of tau aggregates.<sup>
<xref rid="bibr5-0271678X251332487" ref-type="bibr">5</xref>
</sup></p><p>In relevant tau transgenic mouse models, inhibition of O-GlcNAcase (OGA) to increase O-GlcNAcylation in the brain has been shown to protect against pathological tau<sup><xref rid="bibr6-0271678X251332487" ref-type="bibr">6</xref><xref rid="bibr7-0271678X251332487" ref-type="bibr"/>&#8211;<xref rid="bibr8-0271678X251332487" ref-type="bibr">8</xref></sup> and several selective OGA inhibitor drugs have entered clinical trials.<sup><xref rid="bibr9-0271678X251332487" ref-type="bibr">9</xref><xref rid="bibr10-0271678X251332487" ref-type="bibr"/>&#8211;<xref rid="bibr11-0271678X251332487" ref-type="bibr">11</xref></sup> A handful of positron emission tomography (PET) radioligands have been developed for OGA,<sup><xref rid="bibr12-0271678X251332487" ref-type="bibr">12</xref><xref rid="bibr13-0271678X251332487" ref-type="bibr"/><xref rid="bibr14-0271678X251332487" ref-type="bibr"/>&#8211;<xref rid="bibr15-0271678X251332487" ref-type="bibr">15</xref></sup> such tools are not only useful to quantify OGA levels in the living brain but are also instrumental for the direct measurement of OGA level of engagement by drug candidates entering clinical development to establish the relationship between blood concentration and target occupancy.<sup>
<xref rid="bibr16-0271678X251332487" ref-type="bibr">16</xref>
</sup> Understanding the extent to which OGA inhibitors bind to their target is pivotal in selecting a dose and a dose regiment that maximize efficacy and minimize potential side effects, ultimately guiding clinical development decision-making and patient care.<sup>
<xref rid="bibr17-0271678X251332487" ref-type="bibr">17</xref>
</sup></p><p>Among these PET radioligands, BIO-1819578 emerged as a promising high affinity OGA inhibitor candidate (Kd&#8201;=&#8201;2.3&#8201;nM).<sup>
<xref rid="bibr15-0271678X251332487" ref-type="bibr">15</xref>
</sup> As previously reported BIO-1819578, was radiolabelled with <sup>11</sup>C either using [<sup>11</sup>C]CH<sub>3</sub>I at the methyl position<sup>
<xref rid="bibr15-0271678X251332487" ref-type="bibr">15</xref>
</sup> and using [<sup>11</sup>C]CO at the amide group<sup>
<xref rid="bibr18-0271678X251332487" ref-type="bibr">18</xref>
</sup> in our laboratory. Considering the higher radiochemical yield and promising pilot results showing favourable brain kinetics and specificity, the [<sup>11</sup>C]CO labelling synthon was selected for further investigations of [<sup>11</sup>C]BIO-1819578<sup>
<xref rid="bibr18-0271678X251332487" ref-type="bibr">18</xref>
</sup> in the NHP reported in this paper.</p><p>To date, no kinetic compartment analysis of [<sup>11</sup>C]BIO-1819578 has been performed using a radiometabolite corrected arterial plasma input function. As OGA is expressed in blood cells, full quantification using a metabolite corrected input function is required for valid quantification. The primary objective of the present analysis was to describe and interpret [<sup>11</sup>C]BIO-1819578 kinetics in the NHP brain under baseline condition and post administration Thiamet-G at a dose known to significantly engage OGA.<sup>
<xref rid="bibr13-0271678X251332487" ref-type="bibr">13</xref>
</sup> The secondary objective was to determine the effective radiation dose of [<sup>11</sup>C]BIO-1819578 in NHPs, thereby paving the way for safe human use. The results from this study are intended to provide the foundation for further evaluation in human studies. The future aims are to assess the quantification and test-retest reproducibility in humans to support further use in assessing novel disease modifying therapies directed towards OGA activity.</p></sec><sec id="sec2-0271678X251332487"><title>Materials &amp; method</title><p>The study was approved by the Animal Ethics Committee of the Swedish Animal Welfare Agency (Dnr 10367-2019) and was performed according to &#8220;Guidelines for planning, conducting and documenting experimental research&#8221; (Dnr 4820/06-600) of Karolinska Institutet. The NHPs were housed in the Astrid Fagraeus Laboratory (AFL), Comparative Medicine, Karolinska Institutet, Solna, Sweden. AFL is accredited by the organisation AAALAC International for its high quality in animal welfare. The research conducted and the reporting which follows is compliant with ARRIVE guidelines.</p><p>The present compartment analysis of regional [<sup>11</sup>C]BIO-1819578 binding in NHPs was partly based on data obtained in a previously published PET study.<sup>
<xref rid="bibr18-0271678X251332487" ref-type="bibr">18</xref>
</sup> The following is a short description of the sample and imaging procedure in the present and previous study.</p></sec><sec id="sec3-0271678X251332487"><title>Radioligand synthesis</title><p>[<sup>11</sup>C]BIO-1819578 was synthesized and formulated as reported previously.<sup>
<xref rid="bibr18-0271678X251332487" ref-type="bibr">18</xref>
</sup> The synthesis of [<sup>11</sup>C]-carbonmonoxide ([<sup>11</sup>C]CO) was performed using a modified method from previous literature.<sup>
<xref rid="bibr19-0271678X251332487" ref-type="bibr">19</xref>
</sup> No carrier-added [<sup>11</sup>C]CO2 was produced by bombarding a mixture of nitrogen and 0.5% oxygen gas with 16.5&#8201;MeV protons via the <sup>14</sup>&#8201;N(p,&#945;)<sup>11</sup>C nuclear reaction. [<sup>11</sup>C]BIO-1819578 was synthesized by trapping [<sup>11</sup>C]CO at room temperature in a reaction vessel containing the amine precursor (BIO-1952489, 2&#8201;mg), methyl palladium(II) chloride complex (8.0&#8201;mg), and XantPhos (12&#8201;mg) in 400&#8201;&#181;L of THF, followed by heating at 110&#8201;&#176;C for 400&#8201;seconds. After synthesis, 500&#8201;&#181;L of DMSO was added, and THF was evaporated using a helium flow. The resulting residue was diluted with 2&#8201;mL of sterile water before injected into an HPLC for purification, using a semi-preparative reverse phase ACE column. The desired product [<sup>11</sup>C]BIO-1819578 was eluted with a retention time of 10&#8211;11 minutes, diluted with 50&#8201;mL sterile water, and passed through a preconditioned SepPak tC18 plus cartridge for isolation. Finally, the product was eluted with ethanol into a sterile vial, sterile filtered, and the radiochemical purity and stability were assessed using analytical HPLC, confirming the identity of the radiolabeled compound through co-injection with an authentic reference standard.</p><p>The molar activity of the produced radioligand was 17&#8201;&#177;&#8201;6&#8201;GBq/&#956;mol (range, 9&#8211;29&#8201;GBq/&#181;mol) at the time of injection to NHP. The radiochemical purity was &gt;99% at the end of the synthesis. The final product [<sup>11</sup>C]BIO-1819578 formulated in sterile saline was found to be stable with a radiochemical purity of more than 99% for up to 60&#8201;min.</p></sec><sec sec-type="subjects" id="sec4-0271678X251332487"><title>Subjects</title><p>For regional brain quantification of [<sup>11</sup>C]BIO-1819578 data obtained from three adult NHPs, two males and one female cynomolgus monkey, were used (average weight 7.5&#8201;kg, range: 7.2&#8211;8.2&#8201;kg).</p><p>For the dosimetry study two NHPs, one male (also included in the brain studies) and one female, were used (average weight 5.9&#8201;kg, range: 5.3&#8211;6.5&#8201;kg).</p></sec><sec id="sec5-0271678X251332487"><title>Drug administration</title><p>For the baseline-pretreatment study in one of the three NHPs Thiamet-G was administered intravenously for a duration of 5 minutes, 45 minutes prior to PET start, with a dose of 10&#8201;mg/kg and a volume of 1.0&#8201;ml/kg. Pharmacokinetic samples, for venous plasma drug concentration, were acquired at -1-, 1-, 15- and 45-minutes relative the Thiamet-G administration.</p></sec><sec id="sec6-0271678X251332487"><title>Acquisitions</title><p>PET imaging was performed on the High Resolution Research Tomograph (HRRT, CTI/Siemens Medical Solutions). List-mode data was reconstructed with 3&#8201;D-OSEM with point spread function correction using 10 iterations and 16 subsets, with isotropic voxels of 1.22&#8201;mm using a matrix size of 256&#8201;&#215;256&#8201;&#215;&#8201;207.</p><sec id="sec7-0271678X251332487"><title>Brain PET measurement</title><p>Anaesthesia was induced in the NHPs via intramuscular injection of ketamine (10&#8201;mg/kg) and maintained through the administration of a mixture of sevoflurane, oxygen, and medical air with endotracheal intubation. Throughout the PET measurements, the animals&#8217; body temperature, ECG, heart rate, respiratory rate, oxygen saturation, and blood pressure were continuously monitored.</p><p>For brain PET experiments the NHP head was immobilized during the entire PET measurement using a specifically designed head fixation device. Prior to PET acquisition, a 6-minute <sup>137</sup>Cs transmission scan was performed for attenuation and scatter correction purposes. Following an intravenous 10&#8201;s bolus-injection of [<sup>11</sup>C]BIO-1819578 (83&#8201;&#177;&#8201;5&#8201;MBq, 2.0&#8201;&#177;&#8201;1.0&#8201;&#181;g), list-mode data was then acquired dynamically over a total of 93 minutes and reconstructed into 38 frames (10&#8201;s&#8201;&#215;&#8201;9, 15&#8201;s&#8201;&#215;&#8201;2, 20&#8201;s&#8201;&#215;&#8201;3, 30&#8201;s&#8201;&#215;&#8201;4, 1&#8201;min&#8201;&#215;&#8201;4, 3&#8201;min&#8201;&#215;&#8201;4, 6&#8201;min&#8201;&#215;&#8201;12).</p><p>A total of six PET scans were conducted, with five at baseline condition and one in a pretreatment setting. Four baseline PET scans were performed in two NHPs and served as a test-retest evaluation of [<sup>11</sup>C]BIO-1819578.</p></sec><sec id="sec8-0271678X251332487"><title>Dosimetry - Whole body PET measurements</title><p>Anaesthesia preparations and <sup>137</sup>Cs transmission scans were performed in the same manner as for the Brain PET measurements. For each NHP, two PET scans were performed on the same day, each with separate radioligand injections. One scan covered the head to the abdomen (PET scan 1), while the other covered the abdomen to the groin (PET scan 2), to estimate the biodistribution throughout the entire body of the NHP. List-mode data of [<sup>11</sup>C]BIO-1819578 was acquired dynamically over a total of 123 minutes and the 4&#8201;D PET data images were reconstructed in 26 frames (1&#8201;min&#8201;&#215;&#8201;3, 3&#8201;min&#8201;&#215;&#8201;6, 6&#8201;min&#8201;&#215;&#8201;17).</p><p>The mean injected radioactivity of [<sup>11</sup>C]BIO-1819578 was 80&#8201;MBq (PET scan 1: 79&#8201;MBq, PET scan 2: 81&#8201;MBq) and 81&#8201;MBq (PET scan 1: 81&#8201;MBq, PET scan 2: 81&#8201;MBq) for the two NHPs, respectively. The mean molar activity was 19.6&#8201;GBq/&#956;mol (PET scan 1: 14.7&#8201;GBq/&#181;mol, PET scan 2:24.5&#8201;GBq/&#956;mol) and 13.4&#8201;GBq/&#956;mol (PET scan 1: 13.1&#8201;GBq/&#181;mol, PET scan 2: 13.6&#8201;GBq/&#956;mol), respectively, and the mean injected mass was 1.6&#8201;&#956;g (PET scan 1: 1.2&#8201;&#181;g, PET scan 2: 2.0&#8201;&#956;g) and 2.2&#8201;&#956;g (PET scan 1: 2.2&#8201;&#181;g, PET scan 2: 2.2&#8201;&#956;g), respectively.</p></sec><sec id="sec9-0271678X251332487"><title>MRI measurements</title><p>T1-weighted MR imaging was performed on a 1.5-T GE Signa system (General Electric, Milwaukee, WI, USA) using a 3&#8201;D spoiled gradient echo protocol with the following settings: repetition time 21&#8201;ms, flip angle 35&#176;; FOV 12.8&#8201;cm; matrix 256&#8201;&#215;&#8201;256&#8201;&#215;&#8201;128; 1.0&#8201;mm slice thickness; 2 number of excitations.</p></sec><sec id="sec10-0271678X251332487"><title>Arterial blood sampling</title><p>Arterial blood was sampled and measured for radioactivity continuously at a speed of 3&#8201;ml/min for the first 3 minutes of scanning using an Allogg AB automatic blood sampling machine. Discrete samples were acquired for metabolite and radioactivity measurements at 1, 1.5, 2, 2.5, 3, 5, 15, 30, 60, 75 and 90 minutes post radiotracer administration.</p></sec></sec><sec id="sec11-0271678X251332487"><title>Analyses</title><sec id="sec12-0271678X251332487"><title>Radiometabolite analysis</title><p>A reverse-phase high-performance liquid chromatography (HPLC) coupled with ultraviolet (254&#8201;nm) and radioactivity detection was used for determination of the percentages of radioactivity corresponding to [<sup>11</sup>C]BIO-1819578 and its radioactive metabolites during the course of PET measurement, as reported previously.<sup><xref rid="bibr18-0271678X251332487" ref-type="bibr">18</xref>,<xref rid="bibr20-0271678X251332487" ref-type="bibr">20</xref></sup> Arterial plasma samples, obtained at 2, 5, 15, 30, 60, and 75 minutes post-injection, were extracted with acetonitrile to precipitate proteins. Following dilution with water, the extract was injected onto an ACE 5&#8201;&#956;m C18 HL column (250&#8201;&#215;&#8201;10&#8201;mm). Analytes were separated by gradient elution at a flow rate of 5.0&#8201;mL/min, using acetonitrile (A) and 0.1&#8201;M ammonium formate (B) as the mobile phases. The gradient program was as follows: 0&#8201;&#8722;&#8201;4.0&#8201;min, (A/B) 40:60 &#8594; 90:10 v/v; 4.0&#8201;&#8722;&#8201;6.0&#8201;min, (A/B) 90:10 v/v. The fraction of total radioactivity corresponding to the parent radioligand, [<sup>11</sup>C]BIO-1819578, was determined by integrating the area under its chromatographic peak and expressing it as a percentage of the total integrated area of all detected radioactive species.</p></sec><sec id="sec13-0271678X251332487"><title>Radiometabolite-corrected arterial plasma radioactivity curve</title><p>As complete data were not available in all cases due to low signal-to-noise ratio in the radiometabolite analysis, the individual parent fraction estimates were calculated using the Richards function<sup>
<xref rid="bibr21-0271678X251332487" ref-type="bibr">21</xref>
</sup> and a Bayesian population-aided approach. The individual plasma samples and parent fraction estimates were combined to create the radiometabolite-corrected arterial plasma radioactivity curve.</p></sec><sec id="sec14-0271678X251332487"><title>Protein binding</title><p>Using an ultrafiltration method,<sup>
<xref rid="bibr20-0271678X251332487" ref-type="bibr">20</xref>
</sup> the free fraction (f<sub>p</sub>) of [<sup>11</sup>C]BIO-1819578 in plasma was determined for the regional brain quantification study.</p></sec><sec id="sec15-0271678X251332487"><title>Brain image analysis</title><p>The image data were analysed using MatLab 2014&#8201;b (Natick, Massachusetts: The MathWorks Inc.) and an in-house imaging analysis pipeline that performed the kinetic and graphical analysis. The volumes of interest were manually drawn on the T1w MR images for each NHP for whole brain and the regional regions: Putamen, Caudate, Frontal Cortex, Occipital Cortex, Hippocampus, Cerebellum, Thalamus. The coregistration of PET data to MR images was performed using SPM12 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://fil.ion.ucl.ac.uk/spm/" ext-link-type="uri">http://fil.ion.ucl.ac.uk/spm/</ext-link>). The coregistered volumes were applied to the PET data outside of SPM12 to generate time-activity curves of brain regions for each dynamic PET dataset.</p></sec><sec id="sec16-0271678X251332487"><title>Kinetic compartment analysis</title><p>The analysis included the 1-tissue compartment model (1TCM) and the 2-tissue compartment model (2TCM).<sup>
<xref rid="bibr22-0271678X251332487" ref-type="bibr">22</xref>
</sup> The radiometabolite-corrected arterial plasma radioactivity curve was used as input function. The cerebral blood volume (CBV) was fitted using the 2TCM and then applied across all brain regions. As the primary outcome measure, the total distribution volume (<italic toggle="yes">V</italic><sub>T</sub>) was calculated. For the 1TCM, <italic toggle="yes">V</italic><sub>T</sub> was defined as K<sub>1</sub>/k<sub>2</sub>, while for the 2TCM, it was calculated as K<sub>1</sub>/k<sub>2</sub>&#8201;&#215;&#8201;(1&#8201;+&#8201;k<sub>3</sub>/k<sub>4</sub>). The goodness of fit was determined using the second-order corrected Akaike information criteria (AICc).<sup>
<xref rid="bibr23-0271678X251332487" ref-type="bibr">23</xref>
</sup> Time stability of <italic toggle="yes">V</italic><sub>T</sub> was estimated using 2TCM; It was estimated across brain regions during baseline experiments by iteratively calculating <italic toggle="yes">V</italic><sub>T</sub> from progressively shortened time series data.</p></sec><sec id="sec17-0271678X251332487"><title>Graphical analysis</title><p>The Ichise Multilinear Analysis MA1<sup>
<xref rid="bibr24-0271678X251332487" ref-type="bibr">24</xref>
</sup> was also used, as it has been proposed as a reliable graphical modelling approach with improved stability in noisy data compared to other graphical approaches such as Logan graphical analysis, to estimate <italic toggle="yes">V</italic><sub>T</sub> with t* set to 30 minutes, chosen since it provided good fit for all included regions. The coefficient of determination was calculated between <italic toggle="yes">V</italic><sub>T</sub> values from 2TCM and MA1.</p></sec><sec id="sec18-0271678X251332487"><title>Test-retest variability</title><p>The test-retest variability for each region was calculated as: <inline-formula id="ilm1-0271678X251332487">
<mml:math id="mml-math1-0271678X251332487" display="inline" overflow="scroll"><mml:mi mathvariant="italic">TRV</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:mfrac><mml:mrow><mml:msubsup><mml:mo stretchy="false">&#8721;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mfrac><mml:mrow><mml:mfenced close="|" open="|" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="italic">test</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="italic">retest</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="italic">test</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="italic">retest</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math>
</inline-formula>, where <italic toggle="yes">N</italic> denotes the number of subjects, and <italic toggle="yes">test<sub>i</sub></italic> and <italic toggle="yes">retest<sub>i</sub></italic> are the result values of the quantification method.<sup>
<xref rid="bibr25-0271678X251332487" ref-type="bibr">25</xref>
</sup></p></sec><sec id="sec19-0271678X251332487"><title>Parametric imaging</title><p>Wavelet-aided parametric imaging (WAPI)<sup>
<xref rid="bibr26-0271678X251332487" ref-type="bibr">26</xref>
</sup> was used to generate parametric images of [<sup>11</sup>C]BIO-1819578 <italic toggle="yes">V</italic><sub>T</sub> estimates. WAPI employs wavelet filtering to reduce noise and improve the signal-to-noise ratio before applying the Logan&#8217;s graphical approach.</p></sec><sec id="sec20-0271678X251332487"><title>Occupancy estimation after pretreatment with Thiamet-G</title><p>Using the revisited Lassen plot,<sup>
<xref rid="bibr27-0271678X251332487" ref-type="bibr">27</xref>
</sup> occupancy was estimated after pretreatment with Thiamet-G.</p></sec><sec id="sec21-0271678X251332487"><title>Image analysis of the Whole-Body PET</title><p>The whole-body PET image data were analysed using PMOD, version 4.2 (PMOD Technologies LLC). Volumes of interest were drawn on high-uptake organs such as the brain, lung, heart, salivary gland, thyroid, kidney, spleen, liver, gallbladder (only in one NHP), urinary bladder, small intestine, bone (lumbar vertebrae) with the help of the CT images for anatomic landmarks. The absorbed radiation dose in humans was predicted with OLINDA/EXM 1.1 software, using the sex average adult reference model.<sup>
<xref rid="bibr28-0271678X251332487" ref-type="bibr">28</xref>
</sup></p></sec></sec><sec sec-type="results" id="sec22-0271678X251332487"><title>Results</title><sec id="sec23-0271678X251332487"><title>Brain PET data</title><p>All together five baseline PET-measurements were performed in the three NHPs. The time-activity curves for the whole brain peaked at approximately 4.4 SUV on average around 15 minutes post radioligand injection and then decreased to around 3.3 SUV at 90 minutes under baseline conditions. Average regional uptake curves at baseline (n&#8201;=&#8201;5) are presented in Supplemental Figure 1; Regional brain uptake generally peaked at 5&#8211;15 minutes post-injection. <xref rid="fig1-0271678X251332487" ref-type="fig">Figure 1</xref> shows regional time-activity curves in the baseline and pretreatment conditions for NHP 3. Parametric <italic toggle="yes">V</italic><sub>T</sub> images from NHP 3 are shown in <xref rid="fig2-0271678X251332487" ref-type="fig">Figure 2</xref>, demonstrating that pretreatment with Thiamet-G reduced the distribution volume in all brain regions.</p><fig position="float" id="fig1-0271678X251332487" orientation="portrait"><label>Figure 1.</label><caption><p>Compartmental-model curve fitting of [<sup>11</sup>C]BIO-1819578 for Caudate, Occipital Cortex and Cerebellum. Data are from baseline and pretreatment PET of NHP3. A logarithmic time scale was chosen to visualise the early peak difference between the models. 1TCM: 1-tissue compartment model; 2TCM: 2-tissue compartment model.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_0271678X251332487-fig1.jpg"/></fig><fig position="float" id="fig2-0271678X251332487" orientation="portrait"><label>Figure 2.</label><caption><p>Parametric V<sub>T</sub> images of [<sup>11</sup>C]BIO-1819578 at baseline and under pretreatment with Thiamet-G. Both sets of data are overlayed on corresponding MR image in NHP3.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_0271678X251332487-fig2.jpg"/></fig></sec><sec id="sec24-0271678X251332487"><title>Metabolite corrected arterial input function</title><p>The time curve for total radioactivity in arterial plasma was generated using the continuous whole blood and discrete blood and plasma samples. Blood to plasma ratio was best estimated using an exponential fitting method. Extrapolation of the parent fraction estimation, using a Bayesian population-aided approach, was carried out, as low signal to noise was observed in the chromatogram analysis after 60&#8211;75 minutes post injection. On average, the model estimated that 27% of [<sup>11</sup>C]BIO-1819578 remained unmetabolized in NHP plasma at 60 minutes post-injection (Supplemental Figure 2). The time curve for parent fraction and the blood to plasma ratio was used to correct the total radioactivity in arterial blood to obtain the metabolite corrected arterial input function used in the compartment analysis.</p><p>The free fraction was determined to 26%, on average (range 22&#8211;30%), for the baseline experiments and the single estimate after pretreatment with Thiamet-G was also 26%. The metabolite corrected arterial input function was not corrected for f<sub>p</sub>.</p></sec><sec id="sec25-0271678X251332487"><title>Kinetic analysis</title><p>At baseline, both the 1-tissue compartment model (1TCM) and the 2-tissue compartment model (2TCM) were able to describe the time-activity curves in most brain regions (<xref rid="fig1-0271678X251332487" ref-type="fig">Figure 1</xref>), and the Akaike information criterion (AICc) could not separate out a preferable model across regions and subjects (Supplemental Table 1).</p><p>After pretreatment, the 2TCM was the single method that could describe the time-activity curves. <xref rid="fig1-0271678X251332487" ref-type="fig">Figure 1</xref> presents the model estimates for the Caudate, Occipital Cortex, and Cerebellum in NHP3 at baseline and after pretreatment. Combining the baseline data from the three NHPs, 18 out of 35 regions were better estimated using the 2TCM compared to the 1TCM, based on the AICc score. The diagonal panels in <xref rid="fig3-0271678X251332487" ref-type="fig">Figure 3</xref> shows the distribution of individual <italic toggle="yes">V</italic><sub>T</sub> estimates using different modelling methods. The distributions are the narrowest for Cerebellum and Occipital Cortex and the widest for Frontal Cortex and Hippocampus, indicating the level of accuracy for the different models.</p><fig position="float" id="fig3-0271678X251332487" orientation="portrait"><label>Figure 3.</label><caption><p>Correlation plot of V<sub>T</sub> values of the compartmental and graphical models. The diagonal panels show the density plots of individual V<sub>T</sub> estimates. Panels in the lower left show linear regression data between models. 1TCM: 1-tissue compartment model; 2TCM: 2-tissue compartment model; MA1: Ichise Multilinear Analysis 1; Panels in the upper right show R<sup>2</sup> values between models for the different regions. CAU: caudate; CER: cerebellum; FC: frontal cortex; HIP: hippocampus; OC: occipital cortex; PUT: putamen; THA: thalamus.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_0271678X251332487-fig3.jpg"/></fig><p>In the analysis of baseline scans, the 2TCM demonstrated that <italic toggle="yes">V</italic><sub>T</sub> values across different brain regions converged to within 10% of their final values after 66 minutes of image acquisition (Supplemental Figure 3).</p><p>The <italic toggle="yes">V</italic><sub>T</sub> values correlated well between the two models, with an overall R<sup>2</sup> of 0.96 and individual region R<sup>2</sup> ranging from 0.05 to 0. 99 (<xref rid="fig3-0271678X251332487" ref-type="fig">Figure 3</xref>). For the pretreatment data, all regions were preferably modelled using the 2TCM according to the AICc score, and the R<sup>2</sup> between the two compartmental approaches was 0.93. After pretreatment with Thiamet-G, an occupancy of 97.6% (calculated using the 2TCM) was observed, with an estimated <italic toggle="yes">V</italic><sub>ND</sub> of 2.9&#8201;mL&#183;cm<sup>&#8722;3</sup> (Supplemental Figure 4). The individual <italic toggle="yes">V</italic><sub>T</sub> values estimated from the 2TCM are presented in <xref rid="table1-0271678X251332487" ref-type="table">Table 1</xref>.</p><table-wrap position="float" id="table1-0271678X251332487" orientation="portrait"><label>Table 1.</label><caption><p>Regional V<sub>T</sub> values for different models. Presented are median values and the interquartile range.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_0271678X251332487-table1.jpg"/><table frame="hsides" rules="groups"><thead valign="top"><tr><th rowspan="1" colspan="1"/><th colspan="3" rowspan="1">Baseline <italic toggle="yes">V</italic><sub>T</sub> Values [mL&#183;cm<sup>&#8722;3</sup>] median (1<sup>st</sup> Qu.&#8211;3<sup>rd</sup> Qu.)<hr/></th></tr><tr><th rowspan="1" colspan="1">Region</th><th rowspan="1" colspan="1">1TCM</th><th rowspan="1" colspan="1">2TCM</th><th rowspan="1" colspan="1">MA1</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1">Caudate</td><td rowspan="1" colspan="1">25.4 (24.5&#8211;26.4)</td><td rowspan="1" colspan="1">26.4 (25.3&#8211;28.7)</td><td rowspan="1" colspan="1">22.4 (21.9&#8211;32.2)</td></tr><tr><td rowspan="1" colspan="1">Cerebellum</td><td rowspan="1" colspan="1">17.0 (15.8&#8211;17.6)</td><td rowspan="1" colspan="1">17.6 (17.0&#8211;18.1)</td><td rowspan="1" colspan="1">15.8 (15.7&#8211;18.6)</td></tr><tr><td rowspan="1" colspan="1">Frontal Cortex</td><td rowspan="1" colspan="1">26.4 (26.2&#8211;40.8)</td><td rowspan="1" colspan="1">27.2 (26.5&#8211;40.7)</td><td rowspan="1" colspan="1">23.9 (23.3&#8211;26.8)</td></tr><tr><td rowspan="1" colspan="1">Hippocampus</td><td rowspan="1" colspan="1">34.5 (34.1&#8211;36.8)</td><td rowspan="1" colspan="1">34.5 (34.1&#8211;36.8)</td><td rowspan="1" colspan="1">37.6 (31.3&#8211;39.6)</td></tr><tr><td rowspan="1" colspan="1">Occipital Cortex</td><td rowspan="1" colspan="1">18.0 (17.9&#8211;20.5)</td><td rowspan="1" colspan="1">20.5 (17.2&#8211;21.8)</td><td rowspan="1" colspan="1">17.7 (17.2&#8211;18.2)</td></tr><tr><td rowspan="1" colspan="1">Putamen</td><td rowspan="1" colspan="1">25.9 (25.7&#8211;30.1)</td><td rowspan="1" colspan="1">27.6 (26.1&#8211;30.0)</td><td rowspan="1" colspan="1">24.8 (23.7&#8211;28.6)</td></tr><tr><td rowspan="1" colspan="1">Thalamus</td><td rowspan="1" colspan="1">21.3 (19.8&#8211;25.0)</td><td rowspan="1" colspan="1">24.2 (20.9&#8211;25.0)</td><td rowspan="1" colspan="1">19.0 (17.3&#8211;24.0)</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec26-0271678X251332487"><title>Graphical analysis</title><p>MA1 estimates examples are shown in <xref rid="fig4-0271678X251332487" ref-type="fig">Figure 4</xref> and individual <italic toggle="yes">V</italic><sub>T</sub> from MA1 are shown in <xref rid="table1-0271678X251332487" ref-type="table">Table 1</xref>. The correlation between MA1 and the compartmental models are shown in <xref rid="fig3-0271678X251332487" ref-type="fig">Figure 3</xref>. At baseline, the overall R<sup>2</sup> was determined to 0.64 between MA1 and 2TCM, ranging from 0.05 to 0.81 for individual regions. MA1 estimated <italic toggle="yes">V</italic><sub>T</sub> values were negatively biased by approximately 7% compared to those estimated with 2TCM.</p><fig position="float" id="fig4-0271678X251332487" orientation="portrait"><label>Figure 4.</label><caption><p>MA1 curve fitting of [<sup>11</sup>C]BIO-1819578 for Caudate, Occipital Cortex and Cerebellum. Data are from baseline and pretreatment PET of NHP3. t* was set to 30 minutes. MA1: Ichise Multilinear Analysis 1.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_0271678X251332487-fig4.jpg"/></fig></sec><sec id="sec27-0271678X251332487"><title>Test-retest variability</title><p>The regional test-retest variability (<italic toggle="yes">N</italic>&#8201;=&#8201;2) results are presented in <xref rid="table2-0271678X251332487" ref-type="table">Table 2</xref>. Analysis of the data indicate that the 1TCM demonstrated the lowest overall test-retest variability among the models examined.</p><table-wrap position="float" id="table2-0271678X251332487" orientation="portrait"><label>Table 2.</label><caption><p>Test-retest variability for regional brain data for different models.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_0271678X251332487-table2.jpg"/><table frame="hsides" rules="groups"><thead valign="top"><tr><th rowspan="1" colspan="1"/><th colspan="3" rowspan="1">Test-retest variability [%]<hr/></th></tr><tr><th rowspan="1" colspan="1">Region</th><th rowspan="1" colspan="1">1TCM</th><th rowspan="1" colspan="1">2TCM</th><th rowspan="1" colspan="1">MA1</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1">Caudate</td><td align="char" char="." rowspan="1" colspan="1">5.9</td><td align="char" char="." rowspan="1" colspan="1">15.0</td><td align="char" char="." rowspan="1" colspan="1">20.1</td></tr><tr><td rowspan="1" colspan="1">Cerebellum</td><td align="char" char="." rowspan="1" colspan="1">3.6</td><td align="char" char="." rowspan="1" colspan="1">11.6</td><td align="char" char="." rowspan="1" colspan="1">9.4</td></tr><tr><td rowspan="1" colspan="1">Frontal Cortex</td><td align="char" char="." rowspan="1" colspan="1">25.5</td><td align="char" char="." rowspan="1" colspan="1">21.9</td><td align="char" char="." rowspan="1" colspan="1">12.8</td></tr><tr><td rowspan="1" colspan="1">Hippocampus</td><td align="char" char="." rowspan="1" colspan="1">13.7</td><td align="char" char="." rowspan="1" colspan="1">15.7</td><td align="char" char="." rowspan="1" colspan="1">12.1</td></tr><tr><td rowspan="1" colspan="1">Occipital Cortex</td><td align="char" char="." rowspan="1" colspan="1">7.4</td><td align="char" char="." rowspan="1" colspan="1">14.9</td><td align="char" char="." rowspan="1" colspan="1">18.4</td></tr><tr><td rowspan="1" colspan="1">Putamen</td><td align="char" char="." rowspan="1" colspan="1">7.8</td><td align="char" char="." rowspan="1" colspan="1">12.4</td><td align="char" char="." rowspan="1" colspan="1">9.0</td></tr><tr><td rowspan="1" colspan="1">Thalamus</td><td align="char" char="." rowspan="1" colspan="1">16.2</td><td align="char" char="." rowspan="1" colspan="1">16.4</td><td align="char" char="." rowspan="1" colspan="1">14.6</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec28-0271678X251332487"><title>Whole-Body PET and dosimetry</title><p>The magnitude of the [<sup>11</sup>C]BIO-1819578 uptake was broadly similar between the two NHPs, with the greatest uptake observed in the liver, small intestine, brain, kidneys, heart, and bone, all of which peaked at over 1% of the injected radioactivity. The radioligand was primarily excreted via the bile-gastrointestinal tract, and a low bladder accumulation indicated that the urinary tract was only partly the route of excretion during the scanning window (<xref rid="fig5-0271678X251332487" ref-type="fig">Figure 5</xref>). Residence times for organs are presented in Supplemental Table 2. The largest absorbed dose was in the kidneys (0.014 mGy/MBq) (Supplemental Table 3). The calculated human whole-body effective dose was approximately 0.0033 mSv/MBq (Supplemental Table 3).</p><fig position="float" id="fig5-0271678X251332487" orientation="portrait"><label>Figure 5.</label><caption><p>Whole-body PET images of [<sup>11</sup>C]BIO-1819578 in NHP3 and NHP4. Images are decay corrected to time of injection and presented as maximum intensity projection.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_0271678X251332487-fig5.jpg"/></fig></sec></sec><sec sec-type="discussion" id="sec29-0271678X251332487"><title>Discussion</title><p>The study aimed to quantitatively assess the regional brain distribution of the novel radioligand [<sup>11</sup>C]BIO-1819578 in non-human primates under baseline conditions and after pretreatment with the O-GlcNAcase (OGA) inhibitor Thiamet-G. The PET imaging data showed that the calculated regional <italic toggle="yes">V</italic><sub>T</sub> values reflect previous published binding patterns of OGA, with highest binding in hippocampus, striatal regions and the frontal cortex.<sup><xref rid="bibr13-0271678X251332487" ref-type="bibr">13</xref>,<xref rid="bibr15-0271678X251332487" ref-type="bibr">15</xref></sup> The 90-minute PET acquisition of [<sup>11</sup>C]BIO-1819578 in NHPs demonstrated predominantly reversible binding across most brain regions (Supplemental Figure 1). However, in select experiments, high-binding areas such as the frontal cortex and hippocampus exhibit slower radioligand clearance (data not shown). The reversibility is a desirable trait for kinetic modelling, distinguishing [<sup>11</sup>C]BIO-1819578 from previously published <sup>11</sup>C-labeled OGA binding tracers.<sup><xref rid="bibr13-0271678X251332487" ref-type="bibr">13</xref>,<xref rid="bibr15-0271678X251332487" ref-type="bibr">15</xref></sup> Although, most time-activity curves showed reversibility, they also exhibited a fast equilibrium between the two tissue compartments and slow wash-out, leading to the collapse of the 2TCM model into 1TCM for almost all brain regions under baseline conditions. The slow kinetics, particularly in the frontal cortex and hippocampus, lead to challenges in the modelling process, which is reflected in the wide distribution of <italic toggle="yes">V</italic><sub>T</sub> estimates shown in <xref rid="fig3-0271678X251332487" ref-type="fig">Figure 3</xref>. Analysis of the data reveals that the 1TCM exhibits lower overall test-retest variability compared to other models (<xref rid="table2-0271678X251332487" ref-type="table">Table 2</xref>). Additionally, the MA1 model shows promise in reducing variability for the frontal cortex, as evidenced in <xref rid="table2-0271678X251332487" ref-type="table">Table 2</xref>. However, the efficacy of this approach in modelling hippocampal binding remains uncertain. The 2TCM performed better based on the AICc score after pretreatment with Thiamet-G, and the most reliable and valid modelling approach will be further evaluated in future human test-retest studies and applied studies focusing on target occupancy with OGA inhibitors.</p><p>In this study, <italic toggle="yes">V</italic><sub>T</sub> estimated using 2TCM exhibited regional differences with the cerebellum having the lowest values, consistent with saturation studies conducted by Cook et&#160;al. in 2023.<sup>
<xref rid="bibr15-0271678X251332487" ref-type="bibr">15</xref>
</sup> No reference region was identified as no region appeared to be devoid of specific binding for OGA. The estimated <italic toggle="yes">V</italic><sub>T</sub> decreased in all regions, including the cerebellum, after pretreatment with Thiamet-G, further supporting that no evident reference region could be identified. The high occupancy after pretreatment can be explained by the fact that the blood concentration of Thiamet-G was roughly 1500 times higher than the reported K<sub>i</sub> value of 20&#8201;nM<sup>
<xref rid="bibr29-0271678X251332487" ref-type="bibr">29</xref>
</sup> during the pretreatment scan. The estimated <italic toggle="yes">V</italic><sub>ND</sub> was approximately 3&#8201;mL&#183;cm<sup>&#8722;3</sup>, while the <italic toggle="yes">V</italic><sub>T</sub> ranged from 17&#8211;41&#8201;mL&#183;cm<sup>&#8722;3</sup>, indicating that around 84&#8211;93% of <italic toggle="yes">V</italic><sub>T</sub> represents specific binding.</p><p>As reported in by Nag et al.,<sup>
<xref rid="bibr18-0271678X251332487" ref-type="bibr">18</xref>
</sup> the HPLC chromatography analysis of plasma samples did not detect any recirculating lipophilic radiometabolites. Although radiometabolites in the brain cannot be formely excluded, regional brain analysis doesn&#8217;t support the presence of radiometabolites confounding quantification. At baseline the PET data could be adequately described using both the one-tissue (1TCM) and two-tissue (2TCM) compartment models, with metabolite-corrected plasma input function. In contrast to [<sup>18</sup>F]-LSN3316612 time-stability estimates in NHPs,<sup>
<xref rid="bibr12-0271678X251332487" ref-type="bibr">12</xref>
</sup> the analysis for [<sup>11</sup>C]BIO-1819578 showed stable estimates of <italic toggle="yes">V</italic><sub>T</sub> down to 40&#8211;60 minutes, which will be further evaluated in forthcoming human studies. The findings suggest that the formation of blood-brain barrier permeable radiometabolites, which could impact the quantitative analysis, is unlikely but could not be excluded.</p><p>Modelling of the parent fraction using a population-based approach allowed for extrapolation of the data up to the full length of the PET examination. However, this approach may introduce some uncertainty in the fitting of the washout phase and the determination of rate constants k<sub>3</sub> and k<sub>4</sub>, particularly for the three cases where only data up to 60 minutes was available. Nevertheless, the fit as shown in <xref rid="fig1-0271678X251332487" ref-type="fig">Figure 1</xref> shows good fit also at later time points suggesting that the impact of missing data points is likely low. It is still advised that in later studies sample blood for metabolite analyses every fifteen minutes to ensure as many data points as possible, still using a population-based fit for best results.</p><p>The whole-body radiation dosimetry study showed the highest absorbed organ dose was to the kidneys, followed by the gallbladder, heart, and liver. The estimated effective dose (ED) was 0.0033 mSv/MBq of injected radioactivity, which is a relatively low value even for a carbon-11 labelled tracer.<sup>
<xref rid="bibr30-0271678X251332487" ref-type="bibr">30</xref>
</sup> This low ED can likely be attributed to the limited bladder uptake (Supplemental Table 2), which reduces the absorbed dose to nearby radiosensitive organs. It should be noted that the male NHP was castrated and the ED calculation in testis, a region with high OGA expression, did not include any self-dose contribution. Hence, human dosimetry studies are needed for a more accurate testes dose estimation. In future human studies in male subjects the injected activity should be kept low to decrease high ED, as an additional precaution.</p></sec><sec sec-type="conclusions" id="sec30-0271678X251332487"><title>Conclusion</title><p>The results in this study supported previous preliminary findings ensuring that [<sup>11</sup>C]BIO-1819578 has promising characteristics as a PET radioligand for imaging OGA. The radioligand demonstrated high uptake in the brain and clear blocking effects when co-administered with the OGA inhibitor Thiamet-G. The baseline data as well as data from blocking studies could reliably be quantified using both gold standard 2TCM as well as the graphical approach MA1. These findings suggest [<sup>11</sup>C]BIO-1819578 shows high potential to be a suitable PET radioligand for quantifying OGA levels in the human brain. The evaluation of effective dose is also an important step prior to first-in-man studies and the levels are such that human administrated is possible. Further testing of this radioligand in human studies is warranted to assess its potential as a tool for studying OGA-related neurological processes and disorders as well as evaluating novel OGA targeting drugs.</p></sec><sec sec-type="supplementary-material" id="sec103-0271678X251332487" specific-use="figshare"><title>Supplemental Material</title><supplementary-material id="suppl1-0271678X251332487" position="float" content-type="local-data" orientation="portrait"><caption><title>sj-pdf-1-jcb-10.1177_0271678X251332487 - Supplemental material for In vivo quantification of [<sup>11</sup>C]BIO-1819578 in non-human primates, a novel radioligand for O-GlcNAcase</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sj-pdf-1-jcb-10.1177_0271678X251332487.pdf" position="float" orientation="portrait"/><p>Supplemental material, sj-pdf-1-jcb-10.1177_0271678X251332487 for In vivo quantification of [<sup>11</sup>C]BIO-1819578 in non-human primates, a novel radioligand for O-GlcNAcase by Martin Bolin, Sangram Nag, Ryosuke Arakawa, Andrea Varrone, Lars Farde, Laurent Martarello, Maciej A Kaliszczak, Christer Halldin and Anton Forsberg Mor&#233;n in Journal of Cerebral Blood Flow &amp; Metabolism</p></supplementary-material></sec></body><back><ack><title>Acknowledgements</title><p>The authors would like to thank BIOGEN MA Inc. for providing the precursor and reference standard. We are grateful to all members of the PET group at the Karolinska Institutet.</p></ack><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The author(s) received no financial support for the research, authorship, and/or publication of this article.</p></fn></fn-group><fn-group><fn fn-type="COI-statement"><p>The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Martin Bolin, Sangram Nag, Ryosuke Arakawa, Andrea Varrone, Lars Farde, Christer Halldin and Anton Forsberg Mor&#233;n has nothing to disclose.</p><p>Laurent Martarello was a full-time employee of Biogen and received financial compensation at the time of the study.</p><p>Maciej A. Kaliszczak was a full-time employee of Biogen and received financial compensation.</p></fn><fn fn-type="other"><p><bold>Authors&#8217; contributions:</bold> MB analysed the PET data and prepared the manuscript; AFM reviewed and developed PET data analysis protocols; SN developed radiochemical synthesis procedure; RA and AV conceptualized and lead the in vivo study; CH and LF reviewed and developed PET imaging and metabolite analysis protocols; MK and LM contributed to the study design and data analysis.</p><p>All authors have read and agreed to the published version of the manuscript.</p></fn></fn-group><fn-group><fn fn-type="other"><p><bold>ORCID iDs:</bold> Martin Bolin <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0002-7728-6401" ext-link-type="uri">https://orcid.org/0000-0002-7728-6401</ext-link></p><p>Andrea Varrone <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0001-8281-4435" ext-link-type="uri">https://orcid.org/0000-0001-8281-4435</ext-link></p></fn></fn-group><sec><title>Supplementary material</title><p>Supplemental material for this article is available online.</p></sec><ref-list content-type="numbered"><title>References</title><ref id="bibr1-0271678X251332487"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holtzman</surname><given-names>DM</given-names></name><name name-style="western"><surname>Carrillo</surname><given-names>MC</given-names></name><name name-style="western"><surname>Hendrix</surname><given-names>JA</given-names></name></person-group>, <etal>et&#160;al</etal>. 
<article-title>Tau: from research to clinical development</article-title>. <source>Alzheimers Dement</source><year>2016</year>; 
<volume>12</volume>: <fpage>1033</fpage>&#8211;<lpage>1039</lpage>.<pub-id pub-id-type="pmid">27154059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2016.03.018</pub-id></mixed-citation></ref><ref id="bibr2-0271678X251332487"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arendt</surname><given-names>T</given-names></name><name name-style="western"><surname>Stieler</surname><given-names>JT</given-names></name><name name-style="western"><surname>Holzer</surname><given-names>M.</given-names></name></person-group><article-title>Tau and tauopathies</article-title>. <source>Brain Res Bull</source><year>2016</year>; 
<volume>126</volume>: <fpage>238</fpage>&#8211;<lpage>292</lpage>.<pub-id pub-id-type="pmid">27615390</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainresbull.2016.08.018</pub-id></mixed-citation></ref><ref id="bibr3-0271678X251332487"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ossenkoppele</surname><given-names>R</given-names></name><name name-style="western"><surname>Reimand</surname><given-names>J</given-names></name><name name-style="western"><surname>Smith</surname><given-names>R</given-names></name></person-group>, <etal>et&#160;al</etal>. 
<article-title>Tau PET correlates with different Alzheimer&#8217;s disease&#8208;related features compared to CSF and plasma p&#8208;tau biomarkers</article-title>. <source>EMBO Mol Med</source><year>2021</year>; 
<volume>13</volume>: <fpage>e14398</fpage>.<pub-id pub-id-type="pmid">34254442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/emmm.202114398</pub-id><pub-id pub-id-type="pmcid">PMC8350902</pub-id></mixed-citation></ref><ref id="bibr4-0271678X251332487"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>La Joie</surname><given-names>R</given-names></name><name name-style="western"><surname>Visani</surname><given-names>AV</given-names></name><name name-style="western"><surname>Baker</surname><given-names>SL</given-names></name></person-group>, <etal>et&#160;al</etal>. 
<article-title>Prospective longitudinal atrophy in Alzheimer&#8217;s disease correlates with the intensity and topography of baseline tau-PET</article-title>. <source>Sci Transl Med</source><year>2020</year>; 
<volume>12</volume>: <fpage>eaau5732</fpage>.<pub-id pub-id-type="pmid">31894103</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aau5732</pub-id><pub-id pub-id-type="pmcid">PMC7035952</pub-id></mixed-citation></ref><ref id="bibr5-0271678X251332487"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basheer</surname><given-names>N</given-names></name><name name-style="western"><surname>Smolek</surname><given-names>T</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>I</given-names></name></person-group>, <etal>et&#160;al</etal>. 
<article-title>Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer&#8217;s disease? From preclinical studies to the clinical trials</article-title>. <source>Mol Psychiatry</source><year>2023</year>; 
<volume>28</volume>: <fpage>2197</fpage>&#8211;<lpage>2214</lpage>.<pub-id pub-id-type="pmid">37264120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-023-02113-z</pub-id><pub-id pub-id-type="pmcid">PMC10611587</pub-id></mixed-citation></ref><ref id="bibr6-0271678X251332487"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuzwa</surname><given-names>SA</given-names></name><name name-style="western"><surname>Shan</surname><given-names>X</given-names></name><name name-style="western"><surname>Macauley</surname><given-names>MS</given-names></name></person-group>, <etal>et&#160;al</etal>. 
<article-title>Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation</article-title>. <source>Nat Chem Biol</source><year>2012</year>; 
<volume>8</volume>: <fpage>393</fpage>&#8211;<lpage>399</lpage>.<pub-id pub-id-type="pmid">22366723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nchembio.797</pub-id></mixed-citation></ref><ref id="bibr7-0271678X251332487"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hastings</surname><given-names>NB</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Song</surname><given-names>L</given-names></name></person-group>, <etal>et&#160;al</etal>. 
<article-title>Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice</article-title>. <source>Mol Neurodegener</source><year>2017</year>; 
<volume>12</volume>: <fpage>39</fpage>.<pub-id pub-id-type="pmid">28521765</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-017-0181-0</pub-id><pub-id pub-id-type="pmcid">PMC5437664</pub-id></mixed-citation></ref><ref id="bibr8-0271678X251332487"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuzwa</surname><given-names>SA</given-names></name><name name-style="western"><surname>Shan</surname><given-names>X</given-names></name><name name-style="western"><surname>Jones</surname><given-names>BA</given-names></name></person-group>, <etal>et&#160;al</etal>. 
<article-title>Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant mice</article-title>. <source>Mol Neurodegener</source><year>2014</year>; 
<volume>9</volume>: <fpage>42</fpage>.<pub-id pub-id-type="pmid">25344697</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1750-1326-9-42</pub-id><pub-id pub-id-type="pmcid">PMC4232697</pub-id></mixed-citation></ref><ref id="bibr9-0271678X251332487"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kielbasa</surname><given-names>W</given-names></name><name name-style="western"><surname>Phipps</surname><given-names>KM</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>J</given-names></name></person-group>, <etal>et&#160;al</etal>. 
<article-title>A single ascending dose study in healthy volunteers to assess the safety and PK of LY3372689, an inhibitor of O&#8208;GlcNAcase (OGA) enzyme: human/human trials: anti&#8208;tau</article-title>. <source>Alzheimer&#8217;s &amp; Dementia</source><year>2020</year>; 
<volume>16</volume>: <fpage>e040473</fpage>.</mixed-citation></ref><ref id="bibr10-0271678X251332487"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryan</surname><given-names>JM</given-names></name><name name-style="western"><surname>Quattropani</surname><given-names>A</given-names></name><name name-style="western"><surname>Abd-Elaziz</surname><given-names>K</given-names></name></person-group>, <etal>et&#160;al</etal>. 
<article-title>O1&#8208;12&#8208;05: phase 1 study in healthy volunteers of the O&#8208;glcnacase inhibitor asn120290 as a novel therapy for progressive supranuclear palsy and related tauopathies</article-title>. <source>Alzheimer&#8217;s &amp; Dementia</source><year>2018</year>; 
<volume>14</volume>: <fpage>P251</fpage>.</mixed-citation></ref><ref id="bibr11-0271678X251332487"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartolom&#233;-Nebreda</surname><given-names>JM</given-names></name><name name-style="western"><surname>Trabanco</surname><given-names>AA</given-names></name><name name-style="western"><surname>Velter</surname><given-names>AI</given-names></name></person-group>, <etal>et&#160;al</etal>. 
<article-title>O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer&#8217;s disease and related tauopathies: analysis of the patent literature</article-title>. <source>Expert Opin Ther Pat</source><year>2021</year>; 
<volume>31</volume>: <fpage>1117</fpage>&#8211;<lpage>1154</lpage>.<pub-id pub-id-type="pmid">34176417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13543776.2021.1947242</pub-id></mixed-citation></ref><ref id="bibr12-0271678X251332487"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paul</surname><given-names>S</given-names></name><name name-style="western"><surname>Haskali</surname><given-names>MB</given-names></name><name name-style="western"><surname>Liow</surname><given-names>JS</given-names></name></person-group>, <etal>et&#160;al</etal>. 
<article-title>Evaluation of a PET radioligand to image <italic toggle="yes">O</italic> -GlcNAcase in brain and periphery of rhesus monkey and knock-out mouse</article-title>. <source>J Nucl Med</source><year>2019</year>; 
<volume>60</volume>: <fpage>129</fpage>&#8211;<lpage>134</lpage>.<pub-id pub-id-type="pmid">30213846</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.118.213231</pub-id><pub-id pub-id-type="pmcid">PMC6354227</pub-id></mixed-citation></ref><ref id="bibr13-0271678X251332487"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>S</given-names></name><name name-style="western"><surname>Haskali</surname><given-names>MB</given-names></name><name name-style="western"><surname>Ruley</surname><given-names>KM</given-names></name></person-group>, <etal>et&#160;al</etal>. 
<article-title>PET ligands [<sup>18</sup>F]LSN3316612 and [<sup>11</sup> C]LSN3316612 quantify <italic toggle="yes">O</italic>-linked-&#946;-<italic toggle="yes">N</italic>-acetyl-glucosamine hydrolase in the brain</article-title>. <source>Sci Transl Med</source><year>2020</year>; 
<volume>12</volume>: <fpage>eaau2939</fpage>.<pub-id pub-id-type="pmid">32404505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aau2939</pub-id><pub-id pub-id-type="pmcid">PMC8494060</pub-id></mixed-citation></ref><ref id="bibr14-0271678X251332487"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Marcus</surname><given-names>J</given-names></name></person-group>, <etal>et&#160;al</etal>. 
<article-title>MK-8719, a novel and selective <italic toggle="yes">O</italic> -GlcNAcase inhibitor that reduces the formation of pathological tau and ameliorates neurodegeneration in a mouse model of tauopathy</article-title>. <source>J Pharmacol Exp Ther</source><year>2020</year>; 
<volume>374</volume>: <fpage>252</fpage>&#8211;<lpage>263</lpage>.<pub-id pub-id-type="pmid">32493725</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.120.266122</pub-id></mixed-citation></ref><ref id="bibr15-0271678X251332487"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cook</surname><given-names>BE</given-names></name><name name-style="western"><surname>Nag</surname><given-names>S</given-names></name><name name-style="western"><surname>Arakawa</surname><given-names>R</given-names></name></person-group>, <etal>et&#160;al</etal>. 
<article-title>Development of a PET tracer for OGA with improved kinetics in the living brain</article-title>. <source>J Nucl Med</source><year>2023</year>; 
<volume>64</volume>: <fpage>1588</fpage>&#8211;<lpage>1593</lpage>.<pub-id pub-id-type="pmid">37934021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.122.265225</pub-id></mixed-citation></ref><ref id="bibr16-0271678X251332487"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varn&#228;s</surname><given-names>K</given-names></name><name name-style="western"><surname>Varrone</surname><given-names>A</given-names></name><name name-style="western"><surname>Farde</surname><given-names>L.</given-names></name></person-group><article-title>Modeling of PET data in CNS drug discovery and development</article-title>. <source>J Pharmacokinet Pharmacodyn</source><year>2013</year>; 
<volume>40</volume>: <fpage>267</fpage>&#8211;<lpage>279</lpage>.<pub-id pub-id-type="pmid">23660778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10928-013-9320-6</pub-id></mixed-citation></ref><ref id="bibr17-0271678X251332487"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varrone</surname><given-names>A</given-names></name><name name-style="western"><surname>Bundgaard</surname><given-names>C</given-names></name><name name-style="western"><surname>Bang&#8208;Andersen</surname><given-names>B.</given-names></name></person-group><article-title>PET as a translational tool in drug development for neuroscience compounds</article-title>. <source>Clin Pharmacol Ther</source><year>2022</year>; 
<volume>111</volume>: <fpage>774</fpage>&#8211;<lpage>785</lpage>.<pub-id pub-id-type="pmid">35201613</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.2548</pub-id><pub-id pub-id-type="pmcid">PMC9305164</pub-id></mixed-citation></ref><ref id="bibr18-0271678X251332487"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nag</surname><given-names>S</given-names></name><name name-style="western"><surname>Bolin</surname><given-names>M</given-names></name><name name-style="western"><surname>Datta</surname><given-names>P</given-names></name></person-group>, <etal>et&#160;al</etal>. 
<article-title>Development of a novel [<sup>11</sup> C]CO-Labeled positron emission tomography radioligand [<sup>11</sup>C]BIO-1819578 for the detection of <italic toggle="yes">O</italic> -GlcNAcase enzyme activity</article-title>. <source>ACS Chem Neurosci</source><year>2023</year>; 
<volume>14</volume>: <fpage>2560</fpage>&#8211;<lpage>2568</lpage>.<pub-id pub-id-type="pmid">37377046</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acschemneuro.3c00247</pub-id><pub-id pub-id-type="pmcid">PMC10360070</pub-id></mixed-citation></ref><ref id="bibr19-0271678X251332487"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrat</surname><given-names>M</given-names></name><name name-style="western"><surname>Dahl</surname><given-names>K</given-names></name><name name-style="western"><surname>Schou</surname><given-names>M.</given-names></name></person-group><article-title>One&#8208;pot synthesis of <sup>11</sup> C&#8208;labelled primary benzamides via intermediate [<sup>11</sup>C]aroyl dimethylaminopyridinium salts</article-title>. <source>Chemistry</source><year>2021</year>; 
<volume>27</volume>: <fpage>8689</fpage>&#8211;<lpage>8693</lpage>.<pub-id pub-id-type="pmid">33885193</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/chem.202100544</pub-id><pub-id pub-id-type="pmcid">PMC8251633</pub-id></mixed-citation></ref><ref id="bibr20-0271678X251332487"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moein</surname><given-names>MM</given-names></name><name name-style="western"><surname>Nakao</surname><given-names>R</given-names></name><name name-style="western"><surname>Amini</surname><given-names>N</given-names></name></person-group>, <etal>et&#160;al</etal>. 
<article-title>Sample preparation techniques for radiometabolite analysis of positron emission tomography radioligands; trends, progress, limitations and future prospects</article-title>. <source>TrAC Trends in Analytical Chemistry</source><year>2019</year>; 
<volume>110</volume>: <fpage>1</fpage>&#8211;<lpage>7</lpage>.</mixed-citation></ref><ref id="bibr21-0271678X251332487"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giraldo</surname><given-names>J</given-names></name><name name-style="western"><surname>Vivas</surname><given-names>NM</given-names></name><name name-style="western"><surname>Vila</surname><given-names>E</given-names></name></person-group>, <etal>et&#160;al</etal>. 
<article-title>Assessing the (a)symmetry of concentration-effect curves</article-title>. <source>Pharmacol Ther</source><year>2002</year>; 
<volume>95</volume>: <fpage>21</fpage>&#8211;<lpage>45</lpage>.<pub-id pub-id-type="pmid">12163126</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0163-7258(02)00223-1</pub-id></mixed-citation></ref><ref id="bibr22-0271678X251332487"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gunn</surname><given-names>RN</given-names></name><name name-style="western"><surname>Gunn</surname><given-names>SR</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>VJ.</given-names></name></person-group><article-title>Positron emission tomography compartmental models</article-title>. <source>J Cereb Blood Flow Metab</source><year>2001</year>; 
<volume>21</volume>: <fpage>635</fpage>&#8211;<lpage>652</lpage>.<pub-id pub-id-type="pmid">11488533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00004647-200106000-00002</pub-id></mixed-citation></ref><ref id="bibr23-0271678X251332487"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akaike</surname><given-names>H.</given-names></name></person-group><article-title>Likelihood of a model and information criteria</article-title>. <source>J Econometr</source><year>1981</year>; 
<volume>16</volume>: <fpage>3</fpage>&#8211;<lpage>14</lpage>.</mixed-citation></ref><ref id="bibr24-0271678X251332487"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ichise</surname><given-names>M</given-names></name><name name-style="western"><surname>Toyama</surname><given-names>H</given-names></name><name name-style="western"><surname>Innis</surname><given-names>RB</given-names></name></person-group>, <etal>et&#160;al</etal>. 
<article-title>Strategies to improve neuroreceptor parameter estimation by linear regression analysis</article-title>. <source>J Cereb Blood Flow Metab</source><year>2002</year>; 
<volume>22</volume>: <fpage>1271</fpage>&#8211;<lpage>1281</lpage>.<pub-id pub-id-type="pmid">12368666</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.WCB.0000038000.34930.4E</pub-id></mixed-citation></ref><ref id="bibr25-0271678X251332487"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parsey</surname><given-names>RV</given-names></name><name name-style="western"><surname>Slifstein</surname><given-names>M</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>DR</given-names></name></person-group>, <etal>et&#160;al</etal>. 
<article-title>Validation and reproducibility of measurement of 5-HT<sub>1A</sub> receptor parameters with [<italic toggle="yes">carbonyl</italic> - <sup>11</sup>C]WAY-100635 in humans: comparison of arterial and reference tissue input functions</article-title>. <source>J Cereb Blood Flow Metab</source><year>2000</year>; 
<volume>20</volume>: <fpage>1111</fpage>&#8211;<lpage>1133</lpage>.<pub-id pub-id-type="pmid">10908045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00004647-200007000-00011</pub-id></mixed-citation></ref><ref id="bibr26-0271678X251332487"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Csel&#233;nyi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Olsson</surname><given-names>H</given-names></name><name name-style="western"><surname>Farde</surname><given-names>L</given-names></name></person-group>, <etal>et&#160;al</etal>. 
<article-title>Wavelet-aided parametric mapping of cerebral dopamine D2 receptors using the high affinity PET radioligand [11C]FLB 457</article-title>. <source>NeuroImage</source><year>2002</year>; 
<volume>17</volume>: <fpage>47</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">12482067</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/nimg.2002.1152</pub-id></mixed-citation></ref><ref id="bibr27-0271678X251332487"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cunningham</surname><given-names>VJ</given-names></name><name name-style="western"><surname>Rabiner</surname><given-names>EA</given-names></name><name name-style="western"><surname>Slifstein</surname><given-names>M</given-names></name></person-group>, <etal>et&#160;al</etal>. 
<article-title>Measuring drug occupancy in the absence of a reference region: the lassen plot re-visited</article-title>. <source>J Cereb Blood Flow Metab</source><year>2010</year>; 
<volume>30</volume>: <fpage>46</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="pmid">19738632</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/jcbfm.2009.190</pub-id><pub-id pub-id-type="pmcid">PMC2949110</pub-id></mixed-citation></ref><ref id="bibr28-0271678X251332487"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stabin</surname><given-names>MG</given-names></name><name name-style="western"><surname>Sparks</surname><given-names>RB</given-names></name><name name-style="western"><surname>Crowe</surname><given-names>E.</given-names></name></person-group><article-title>OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine</article-title>. <source>J Nucl Med</source><year>2005</year>; 
<volume>46</volume>: <fpage>1023</fpage>&#8211;<lpage>1027</lpage>.<pub-id pub-id-type="pmid">15937315</pub-id></mixed-citation></ref><ref id="bibr29-0271678X251332487"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuzwa</surname><given-names>SA</given-names></name><name name-style="western"><surname>Macauley</surname><given-names>MS</given-names></name><name name-style="western"><surname>Heinonen</surname><given-names>JE</given-names></name></person-group>, <etal>et&#160;al</etal>. 
<article-title>A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo</article-title>. <source>Nat Chem Biol</source><year>2008</year>; 
<volume>4</volume>: <fpage>483</fpage>&#8211;<lpage>490</lpage>.<pub-id pub-id-type="pmid">18587388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nchembio.96</pub-id></mixed-citation></ref><ref id="bibr30-0271678X251332487"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zanotti-Fregonara</surname><given-names>P</given-names></name><name name-style="western"><surname>Innis</surname><given-names>RB.</given-names></name></person-group><article-title>Suggested pathway to assess radiation safety of 11C-labeled PET tracers for first-in-human studies</article-title>. <source>Eur J Nucl Med Mol Imaging</source><year>2012</year>; 
<volume>39</volume>: <fpage>544</fpage>&#8211;<lpage>547</lpage>.<pub-id pub-id-type="pmid">22160195</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-011-2005-8</pub-id><pub-id pub-id-type="pmcid">PMC3791506</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>